Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer.
Prostate Biomarkers trial in metastatic hormone-sensitive prostate cancer (mHSPC) tests whether circulating tumor deoxyribonucleic acid (ctDNA) can personalize first-line treatment for mHSPC by safely de-escalating therapy in patients with undetectable ctDNA and by intensifying biomarker-matched treatment in ctDNA-detectable disease, aiming to preserve outcomes while reducing toxicity and improving quality of life.
Authors
- Ashkan Mortezavi (ORCID: https://orcid.org/0000-0001-6307-2659)
- Christoph Müller (ORCID: https://orcid.org/0000-0003-1746-6088)
- Johan Lindberg (ORCID: https://orcid.org/0000-0003-4227-6374)
- Andreas Røder
- Andrea Discacciati
- Piet Ost
- Henrik Grönberg
- Antti Rannikko
- Bram De Laere
- Martin Eklund
- Alessio Crippa
Institutions
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
- Copenhagen University Hospital (DK)
- Karolinska Institutet (SE)
- Ghent University (BE)
- University Hospital of Zurich (CH)
- Iridium Kankernetwerk (BE)
- Sørlandet Sykehus (NO)
Publication Details
- Journal
- PubMed
- Published
- 2026-05-12
- DOI
- https://doi.org/10.1016/j.euf.2026.04.018
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00